The Crisis of Antimicrobial Resistance in Helicobacter pylori
Helicobacter pylori (H pylori) remains one of the most prevalent bacterial infections worldwide, affecting approximately half of the global population. It is the primary etiological agent for chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma. For decades, the standard of care has relied on empirical triple or quadruple antibiotic therapies. However, the efficacy of these regimens has plummeted due to the rapid emergence of antimicrobial resistance (AMR), particularly against clarithromycin and levofloxacin. The World Health Organization has categorized clarithromycin-resistant H pylori as a high-priority pathogen, emphasizing the urgent need for innovative diagnostic and therapeutic strategies.
Traditional antimicrobial susceptibility testing (AST) for H pylori is notoriously difficult. The bacterium is fastidious, requiring specific growth conditions and long incubation periods, which often leads to low culture success rates in clinical settings. Consequently, clinicians frequently prescribe antibiotics without knowing the resistance profile of the specific strain infecting the patient. This empirical approach not only risks treatment failure but also drives further resistance. A recent landmark study published in Lancet Microbe by Martínez-Martínez and colleagues provides a robust genomic framework to transition from empirical to personalized, genotype-based H pylori management.
Highlights of the Genomic Determinants Study
The study offers critical insights into the molecular landscape of H pylori resistance, summarized by these key takeaways:
- Genomic markers in the 23S rRNA and gyrA genes predict resistance to clarithromycin and levofloxacin with 100% sensitivity and specificity.
- Specific mutations are directly correlated with distinct elevations in Minimum Inhibitory Concentrations (MICs), allowing for the prediction of the degree of resistance.
- Resistance prevalence is highly region-specific, with some areas exceeding 50% resistance for key antibiotics, making empirical therapy clinically untenable.
- The study establishes a curated catalogue of mutations that can serve as a gold standard for future molecular diagnostic assays.
Study Design and Methodological Rigor
This retrospective phenotypic and genotypic observational study utilized a massive dataset from the H pylori Genome Project (HpGP). The researchers analyzed 1,011 H pylori whole-genome sequences (WGS) with known geographic origins. To validate the genomic findings, phenotypic AST was performed on a subset of 419 strains using the Etest method at a centralized laboratory.
The genomic analysis focused on identifying variants in the 23S rRNA gene (associated with clarithromycin resistance) and the gyrA gene (associated with levofloxacin resistance). By comparing these genotypes with phenotypic MIC values, the team built a curated catalogue of resistance-associated mutations. To broaden the scope, they integrated an additional 768 WGS from the US National Center for Biotechnology Information (NCBI) Sequence Read Archive, resulting in a combined dataset of 1,779 genomes for global prevalence mapping.
Key Findings: The Genetic Signature of Resistance
Clarithromycin Resistance and 23S rRNA
The study confirmed that clarithromycin resistance is primarily driven by three specific mutations in the 23S rRNA gene: 2142A→G, 2142A→C, and 2143A→G. The genotype-phenotype concordance was remarkable, achieving a sensitivity and specificity of 100% (95% CI 96–100). Interestingly, the specific mutation influenced the level of resistance. Strains with the 2142A→G mutation exhibited a significantly higher mean clarithromycin MIC (142.25 mg/L) compared to those with the 2143A→G mutation (24.61 mg/L). This suggests that genomic testing can provide more than just a binary ‘resistant/susceptible’ result; it can quantify the severity of resistance.
Levofloxacin Resistance and gyrA
For levofloxacin, mutations in the quinolone resistance-determining region (QRDR) of the gyrA gene were the primary determinants. Key mutations included A88V/P, N87K/I, and D91G/N/Y. Similar to clarithromycin, these markers yielded 100% sensitivity and specificity. The researchers noted that mutations at codon 87 resulted in higher mean MICs (27.97 mg/L) than mutations at codon 91 (9.66 mg/L). This granularity is vital for clinicians considering higher-dose regimens or alternative fluoroquinolones.
Global Prevalence and Regional Disparities
The combined analysis of 1,779 genomes revealed staggering regional variations in resistance. Clarithromycin resistance was most prevalent in the Western Pacific region, specifically Southeast Asia (51.2%) and Eastern Asia (29.8%). High rates were also noted in North Africa (38.9%) and Western Asia (31.6%). Levofloxacin resistance showed a different geographic footprint, peaking in South Asia (51.85%), Central America (38.7%), and Eastern Europe (36.4%). These data suggest that the ‘standard’ triple therapy is likely to fail in more than half of the patients in certain parts of the world.
Clinical Implications and Expert Commentary
The implications of this study are profound for the field of gastroenterology and infectious diseases. The 100% concordance between genotype and phenotype validates the use of molecular diagnostics as a primary tool for H pylori management. In many clinical settings, molecular methods like PCR or WGS are faster and more reliable than traditional culture.
Experts suggest that the era of empirical therapy for H pylori should come to an end. Given the high prevalence of resistance documented in this study, prescribing clarithromycin or levofloxacin without prior susceptibility testing is increasingly viewed as suboptimal care. However, the transition to precision medicine faces hurdles, including the cost of sequencing and the need for standardized diagnostic platforms in low-resource settings.
One limitation of the study is its retrospective nature and the focus on only two antibiotic classes. While clarithromycin and levofloxacin are critical, resistance to metronidazole and amoxicillin also requires further genomic clarification. Additionally, while gyrA and 23S rRNA are dominant markers, secondary or compensatory mutations might exist that were not fully captured in this analysis.
Conclusion: Moving Toward Pathogen-Based Personalized Therapy
The work of Martínez-Martínez et al. provides a definitive evidence base for the use of genomic markers in H pylori treatment. By identifying reliable genetic determinants of resistance, the study paves the way for the development of rapid diagnostic assays that can be used at the point of care. For the clinician, the message is clear: understanding the genetic profile of the infecting strain is the most effective way to ensure treatment success and steward our remaining antibiotic resources. As genomic technologies become more accessible, the goal of ‘test, profile, and treat’ is finally within reach for H pylori management.
Funding and References
Funding for this research was provided by the Intramural Research Program of the US National Cancer Institute, the European Research Council, and the Spanish Ministry of Science and Innovation.
Reference:
Martínez-Martínez FJ, Chiner-Oms Á, Furió V, et al. Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study. Lancet Microbe. 2026; doi: 10.1016/j.lanmic.2025.101217.
